

Supplementary materials:**Title:**

COVID-19 in children in NSW, Australia, during the 2021 Delta outbreak: Severity and Disease spectrum

Authors:

Phoebe Williams*^{1,2,3,4}, Archana Koirala*^{1,2,3}, Gemma Saravanos*^{1,3}, Laura Lopez*², Catherine Glover², Ketaki Sharma^{1,2}, Tracey Williams^{1,3}, Emma Carey^{1,2}, Nadine Shaw¹, Emma Dickins¹, Neela Sitaram¹, Joanne Ging¹, Paula Bray¹, Nigel Crawford⁵, Brendan McMullan^{1,4}, Kristine Macartney^{1,2,3}, Nicholas Wood^{1,2,3}, Beth Fulton¹, Christine Lau¹, Philip N Britton^{1,2,3}.

*Contributed equally

Affiliations:

1. Sydney Children's Hospitals Network;
2. National Centre for Immunisation Research and Surveillance;
3. Faculty of Medicine and Health, University of Sydney;
4. School of Women's and Children's Health, University of New South Wales; NSW, Australia.
5. Royal Children's Hospital and Murdoch Children's Research Institute, Melbourne, Victoria, Australia.

Correspondance :

A/Prof Philip Britton

The Children's Hospital at Westmead Clinical School

Locked Bag 4001, Westmead NSW Australia 2145

Email: philip.britton@health.nsw.gov.au

Supplementary Methods:

Data sources and data use for calculation of rates.

Data Source	Numerator	Denominator	Metric
Paediatric Active Enhanced Disease Surveillance (PAEDS)	SARS-CoV-2 associated ICU Admissions at SCHN		COVID-19 ICU admission 'rate'
PAEDS	PIMS-TS Admissions at SCHN		PIMS-TS admission 'rate'*
NSW Ministry of Health		Statewide age-specific SARS-CoV-2 infection	
PAEDS	SARS-CoV-2 associated 'Medical' Admissions at SCHN		COVID-19 hospital admission 'rate'
SCHN 'Home in the Hospital' program (Social admissions)	SARS-CoV-2 associated Social Admissions at SCHN		COVID-19 social vulnerability 'rate'
SCHN VirtualKIDS-CORT		SARS-CoV-2 associated Admissions at SCHN	

Abbreviations: ICU=intensive care unit; NSW=New South Wales, Australia; PIMS-TS= paediatric inflammatory multi-system syndrome temporally associated with SARS-CoV-2; SCHN=Sydney Children's Hospital Network

*PIMS-TS = paediatric inflammatory multi-system syndrome temporally associated with SARS-CoV-2 infection; admission rate calculated using data cut of at 30 September, 2021 given lag time for this 'post-infectious' clinical manifestation.

Supplementary Results:

Supplementary Table 1: Case fatality and admission rates overall and by age group and severity of disease amongst cases of SARS-CoV-2 infection managed by SCHN hospitals June - October 2021.

	Rate per 100 infections [95%CI if applicable]					
	0-15 years	0-5 months	6-23 months	2-4 years	5-11 years	12-15 years
Death (n=1)	0.005	-	-	-	-	0.02
ICU Admit (n=15)	0.09	0.20	0.06	-	0.05	0.21
Medical Admit + ICU Admit (n=165)	1.38 [1.17 - 1.59]	12.0 [8.9-15.1]	2.3 [1.5-3.2]	0.9 [0.5-1.3]	0.5 [0.3-0.7]	1.4 [1.0-1.8]
PIMS-TS* (n=7)	0.04	0.20	0.06	0.09	0.03	-

*PIMS-TS=paediatric inflammatory multi-system syndrome temporally associated with SARS-CoV-2 infection; admission rate calculated using notification data cut of at 30 September, 2021 given lag time for this 'post-infectious' clinical manifestation.


Supplementary Table 2. Full list of clinical features, treatment and outcomes among cases of SARS-CoV-2 infection admitted to SCHN by highest acuity level of care amongst children aged 0-15 years managed through SCHN, June 1 - October 31, 2021.

Characteristic	VirtualKIDS-CORT sample, N = 344 ¹	Medical (non-ICU) admission, N = 150 ¹	ICU admission, N = 15 ¹	P value ²
Symptomatic	233 / 344 (68%)	150 / 150 (100%)	15 / 15 (100%)	<0.001
Fever	30 / 219 (14%)	99 / 144 (69%)	12 / 15 (80%)	<0.001
Cough	116 / 232 (50%)	108 / 149 (72%)	12 / 15 (80%)	<0.001
Rhinorrhoea	117 / 232 (50%)	90 / 148 (61%)	8 / 15 (53%)	0.14
Ear pain	2 / 230 (0.9%)	1 / 131 (0.8%)	0 / 14 (0%)	>0.9
Oropharyngeal pain	51 / 230 (22%)	14 / 130 (11%)	5 / 14 (36%)	0.005
Dyspnoea	6 / 232 (2.6%)	43 / 146 (29%)	7 / 15 (47%)	<0.001
Wheeze	2 / 232 (0.9%)	6 / 145 (4.1%)	0 / 15 (0%)	0.10
Chest pain	1 / 230 (0.4%)	15 / 130 (12%)	1 / 14 (7.1%)	<0.001
Chest indraw	0 / 232 (0%)	6 / 146 (4.1%)	0 / 15 (0%)	0.005
Myalgia	31 / 230 (13%)	11 / 128 (8.6%)	6 / 14 (43%)	0.004
Arthralgia	12 / 230 (5.2%)	5 / 128 (3.9%)	2 / 14 (14%)	0.2
Fatigue/malaise	66 / 232 (28%)	56 / 143 (39%)	10 / 15 (67%)	0.003
Anosmia	23 / 231 (10.0%)	15 / 129 (12%)	3 / 14 (21%)	0.3
Hypogeusia	29 / 230 (13%)	14 / 129 (11%)	4 / 14 (29%)	0.2
Vomiting/nausea	21 / 232 (9.1%)	52 / 145 (36%)	7 / 15 (47%)	<0.001
Headache	70 / 230 (30%)	32 / 129 (25%)	8 / 14 (57%)	0.042
Diarrhoea	23 / 232 (9.9%)	42 / 147 (29%)	7 / 15 (47%)	<0.001
Confusion/altered consciousness	0 / 232 (0%)	4 / 145 (2.8%)	3 / 15 (20%)	<0.001
Seizure	0 / 232 (0%)	2 / 145 (1.4%)	1 / 15 (6.7%)	0.020
Abdominal pain	11 / 231 (4.8%)	19 / 132 (14%)	2 / 14 (14%)	0.003
Conjunctivitis	15 / 232 (6.5%)	11 / 145 (7.6%)	0 / 15 (0%)	0.7
Rash	10 / 232 (4.3%)	6 / 145 (4.1%)	3 / 15 (20%)	0.055
Ulcers	1 / 232 (0.4%)	0 / 145 (0%)	0 / 15 (0%)	>0.9
Lymphadenopathy	0 / 232 (0%)	3 / 145 (2.1%)	0 / 15 (0%)	0.11
Bleeding/haemorrhage	0 / 232 (0%)	2 / 145 (1.4%)	1 / 15 (6.7%)	0.020
Other ³	19 / 232 (8.2%)	77 / 149 (52%)	10 / 15 (67%)	<0.001
Co-pathogen detected	0 / 343 (0%)	9 / 150 (6.0%)	2 / 15 (13%)	<0.001
Medication provided				
Antibiotics	1 / 50 (2.0%)	49 / 116 (42%)	13 / 15 (87%)	<0.001
Antivirals	0 / 50 (0%)	1 / 116 (0.9%)	8 / 15 (53%)	<0.001
Antifungals	0 / 50 (0%)	1 / 115 (0.9%)	2 / 15 (13%)	0.019
Corticosteroids	0 / 50 (0%)	18 / 116 (16%)	14 / 15 (93%)	<0.001
Systemic anticoagulation	NA	6 / 115 (5.2%)	10 / 15 (67%)	<0.001
Respiratory support				<0.001
None	NA	134 / 144 (93%)	1 / 15 (6.7%)	
Low flow oxygen	NA	7 / 144 (4.9%)	2 / 15 (13%)	
High flow oxygen	NA	3 / 144 (2.1%)	2 / 15 (13%)	
Non-invasive ventilation	NA	0 / 144 (0%)	3 / 15 (20%)	
Invasive ventilation	NA	0 / 144 (0%)	7 / 15 (47%)	
Length of stay (days)	NA	2 (1, 8)	7 (4, 11)	0.015
Death	0 / 344 (0%)	0 / 150 (0%)	1 / 15 (6.7%)	0.029

Boldfaced P values are significant at an alpha level of 0.05. Abbreviations: ICU, intensive care unit. Numerator and denominator data source is PAEDS. Denominators less than the sample size (N) are due to missing data.


¹n / N (%);²Fisher's exact test; Pearson's Chi-squared test; ³Heterogeneous mix of symptoms.

Supplementary Figure 1. Proportion of children with symptoms ($n \geq 10^*$) among cases of acute SARS-CoV-2 infection admitted to SCHN by highest acuity level of care amongst children aged 0-15 years managed through SCHN, June 1 - October 31, 2021.



*Excluded from figure: Wheeze ($n = 8$), Chest indraw ($n = 6$), Confusion/altered consciousness ($n = 7$), Seizure ($n = 3$), Ulcer ($n = 1$), Lymphadenopathy ($n = 3$), Haemorrhage ($n = 3$).

Supplementary Figure 2. Proportion of symptoms by age group ($n \geq 10^*$) among cases of acute SARS-CoV-2 infection (hospitalised (non-ICU and ICU) and VirtualKIDS-CORT) managed through SCHN, June 1 - October 31, 2021.



*Excluded from figure: Wheeze ($n = 8$), Chest indraw ($n = 6$), Confusion/altered consciousness ($n = 7$), Seizure ($n = 3$), Ulcer ($n = 1$), Lymphadenopathy ($n = 3$), Haemorrhage ($n = 3$).